Methoxpropamine, also known as MXPr and 2-Oxo-3′-methoxy-PCPr, falls within the category of dissociative anesthetic drugs belonging to the arylcyclohexylamine class. It functions as an NMDA receptor antagonist. Methoxpropamine shares structural similarities with other substances like methoxetamine and PCPr. This compound has been marketed online as a designer drug and was initially detected in Denmark in October 2019. It is important to note that Methoxpropamine is considered illegal in Finland.

IUPAC name
CAS Number2504100-71-2 
PubChem CID155817932
Chemical and physical data
Molar mass261.365 g·mol−1


1. What is Methoxpropamine (MXPr)?

Methoxpropamine, often referred to as MXPr, is a dissociative anesthetic drug categorized under the arylcyclohexylamine class. It acts as an NMDA receptor antagonist and shares structural similarities with substances like methoxetamine and PCPr.

2. What are the common names for Methoxpropamine?

MXPr is typically known as Methoxpropamine. However, it may also be referred to by its chemical name, 2-Oxo-3′-methoxy-PCPr.

3. How is Methoxpropamine used?

Methoxpropamine is commonly ingested orally, although it may also be used intranasally. It is often available in powder or crystalline form. The use of MXPr carries potential health risks and legal implications in many regions.

4. Is Methoxpropamine legal?

The legal status of Methoxpropamine can vary from one country or jurisdiction to another. In some places, it may be classified as a controlled or illegal substance, while in others, it may be unregulated or allowed for research purposes. Ensure you are aware of the specific regulations in your area.

5. What are the effects of Methoxpropamine?

The effects of MXPr are similar to those of other dissociative anesthetics. Users may experience altered perception, hallucinations, a sense of disconnection from reality, and changes in sensory experiences. The intensity and duration of these effects can differ from person to person.

6. What are the potential risks and side effects of using Methoxpropamine?

The use of Methoxpropamine can lead to various adverse effects, including disorientation, confusion, nausea, anxiety, and potential risks to physical and mental health. Extended use may result in adverse health outcomes, including kidney and bladder issues.

7. Can Methoxpropamine be addictive?

The addictive potential of Methoxpropamine is not well-researched, but like other dissociative anesthetics, it may carry the risk of psychological dependence, especially with frequent or heavy use.

8. Is it safe to use Methoxpropamine?

Safety concerns surround the use of Methoxpropamine due to limited research and potential adverse effects. Using MXPr can be risky, and its safety is not guaranteed, mainly when obtained from unregulated sources.

9. Can Methoxpropamine be detected in drug tests?

Methoxpropamine is not commonly included in standard drug tests. However, specialized testing may be capable of detecting its presence. It is essential to be aware of the testing methods used in your specific situation.

10. What should I do if I or someone I know is experiencing adverse effects from Methoxpropamine use?

If you or someone you know is experiencing adverse effects or health concerns related to Methoxpropamine use, seek immediate medical attention. Be honest with healthcare professionals about substance use to ensure proper care and treatment.

11. Where can I find reliable information about Methoxpropamine?

For accurate and up-to-date information on Methoxpropamine, consult trusted sources such as government health agencies, substance abuse prevention organizations, and medical professionals. Always exercise caution and prioritize your safety when researching and considering the use of substances like MXPr.


  1. In a study published in July 2021, Irie T, Yamazaki D, and Kikura-Hanajiri R explored the potential of Methoxpropamine as a widespread recreational drug. Their research indicated that Methoxpropamine has the capability to block NMDA receptors and inhibit NMDA receptor-mediated synaptic transmission in a brain preparation of mice. This study was featured in “Forensic Toxicology,” Volume 39, Issue 2, with the identifier doi:10.1007/s11419-021-00571-0.
  2. In April 2022, a research team consisting of Goncalves, R.; Castaing, N.; Richeval, C.; Ducint, D.; Titier, K.; Morvan, E.; Grélard, A.; Loquet, A.; and Molimard, M. conducted an analytical characterization of Methoxpropamine (MXPr) in powder, urine, and hair samples. Their study also involved the identification of metabolites related to this emerging threat. This research was published in “Forensic Science International,” Volume 333, and can be referenced with the identifier doi:10.1016/j.forsciint.2022.111215.
  3. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) issued a “EU Early Warning System Situation Report” in June 2020. This report provides valuable insights into the current situation concerning Methoxpropamine and other substances of concern.
  4. Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista (Finnish Government Decree on Banned Psychoactive Substances in Consumer Markets) outlines the legal restrictions and prohibitions related to Methoxpropamine and similar substances in Finland. This regulatory framework is essential for understanding the legal status of Methoxpropamine in the country.

Leave a Comment

Your email address will not be published. Required fields are marked *